Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis

Dafni, Urania; Lluesma, Silvia Martin; Balint, Klara; Tsourti, Zoi; Vervita, Katerina; Chenal, J.; Coukos, George; Zaman, Khalil; Sarivalasis, Apostolos; Kandalaft, Lana E.

doi:10.1016/j.ejca.2020.10.014

Cited by 24 publications

(36 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, BC represents the third most studied tumour for cancer vaccination, following melanoma and cervical cancer [ 23 ]. Historically, the most common TAAs targeted in BC are HER2, Mucin 1, cell surface associated (MUC-1), carcinoembryonic antigen (CEA) and human telomerase reverse transcriptase (hTERT) [ 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic vaccines for breast cancer: Has the time finally come?

Corti

Giachetti

Eggermont

et al. 2022

European Journal of Cancer

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Therapeutic vaccines for breast cancer: Has the time finally come?

Corti

Giachetti

Eggermont

et al. 2022

European Journal of Cancer

View full text Add to dashboard Cite

“…[101][102][103] Overall, most trials demonstrated low therapeutic effects with a median PFS of 13.0 months, mainly due to the low expression of the target antigen, tumor heterogeneity, and the patient population. 100,104 A prolongation of PFS and OS in recurrent EOC was demonstrated in several clinical trials investigating the efficacy of NY-ESO-1-based vaccines, 105,106 dendritic cell (DC) vaccines based on a pool of peptides (Her2/neu, hTERT, and PADRE peptides), 107 or whole-tumor vaccines of autologous tumor cells infected with Newcastle disease virus, 108 or viral oncolysate vaccine generated from EOC cell lines infected with influenza-A virus. 109 DC vaccination with whole-tumor lysate might be a relevant strategy for EOC treatment, as surgery is a crucial component of EOC treatment, and therefore sufficient tumoral material should be available (Figure 1).…”

Section: Dendritic-cell Vaccinationmentioning

confidence: 99%

Cell therapies in ovarian cancer

et al. 2021

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the most important cause of gynecological cancer-related mortality. Despite improvements in medical therapies, particularly with the incorporation of drugs targeting homologous recombination deficiency, EOC survival rates remain low. Adoptive cell therapy (ACT) is a personalized form of immunotherapy in which autologous lymphocytes are expanded, manipulated ex vivo, and re-infused into patients to mediate cancer rejection. This highly promising novel approach with curative potential encompasses multiple strategies, including the adoptive transfer of tumor-infiltrating lymphocytes, natural killer cells, or engineered immune components such as chimeric antigen receptor (CAR) constructs and engineered T-cell receptors. Technical advances in genomics and immuno-engineering have made possible neoantigen-based ACT strategies, as well as CAR-T cells with increased cell persistence and intratumoral trafficking, which have the potential to broaden the opportunity for patients with EOC. Furthermore, dendritic cell-based immunotherapies have been tested in patients with EOC with modest but encouraging results, while the combination of DC-based vaccination as a priming modality for other cancer therapies has shown encouraging results. In this manuscript, we provide a clinically oriented historical overview of various forms of cell therapies for the treatment of EOC, with an emphasis on T-cell therapy.

show abstract

“…Currently, the incidence of OC is increasing worldwide with the affected population getting younger. In 2018, globally, there were more than 290,000 new cases and approximately 185,000 OC-related deaths (4,5). At present, the main treatment methods include radical OC surgery, cytoreductive surgery, and platinum combined with paclitaxel chemotherapy; however, the 5-year survival rate remains poor (6).…”

Section: Introductionmentioning

confidence: 99%

Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer

Chen

Zhang

et al. 2021

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Objective: To investigate the levels of plasma exosome-derived fragile-site associated tumor suppressor (FATS) and evaluate its predictive ability in ovarian cancer (OC) patients. Patients and Methods: Exosome-rich fractions were isolated from the plasma of enrolled 90 patients with OC. The levels of plasma exosome-derived FATS were detected with ELISA. Results: The levels of exosome-derived FATS in OC patient were significantly lower than in healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with low grade (1/2), FIGO stages I/II than high grade (3/4), stages III/ IV disease (P = 0.003; P < 0.001). The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis, no ascites than those with lymph node metastasis, ascites (both P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with CA-125 less than 35U/ml than more than 35U/ml (P < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients who had low plasma exosome-derived FATS levels than that high levels (both P < 0.001). The AUROC of plasma exosome-derived FATS were 0.85(95% CI: 0.76-0.91) for 5-DFS, 0.91(95% CI: 0.83-0.96) for 5-OS prediction in patients with OC, respectively. Conclusions: Plasma exosome-derived FATS levels in OC patient were significantly down-regulated. Low levels of plasma exosome-derived FATS had close relationship with FIGO stages I/II, low grade, ascites, higher levels of CA-125, lymph node metastasis and prognosis of OC patients. Our findings may provide a new strategy in treating OC.

show abstract

Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis

Cited by 24 publications

References 111 publications

Therapeutic vaccines for breast cancer: Has the time finally come?

Therapeutic vaccines for breast cancer: Has the time finally come?

Cell therapies in ovarian cancer

Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer

Contact Info

Product

Resources

About